๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia
NCT06729320Refractory Immune Effector Cell-related Hemocytopenia
Beijing GoBroad Hospital
Not applicable
40
Beijing
2024-12-01
Recruiting
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
NCT06926179Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery
Peking University Cancer Hospital & Institute
Observational
500
Beijing, Hohhot, Kunming
2024-12-01
Not yet open
A Novel Classification of Sagittal Spinal Alignment to Aid Surgical Planning for Adult Spinal Deformity
NCT06470152Adult Spinal Deformity, Sagittal Deformity, Sagittal Alignment, Sagittal Imbalance
Xuanwu Hospital, Beijing
Not applicable
200
Beijing
2024-12-01
Recruiting
Adaptive Radiotherapy for Genitourinary Cancers
NCT07324798Prostate Cancer (Post Prostatectomy), Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
60
Beijing
2024-12-01
Recruiting
Risk Stratification and MRD-driven Maintenance for MM After ASCT
NCT06697483Multiple Myeloma
DrugsDaratumumab·Lenalidomide
Peking University People's Hospital
Not applicable
100
Beijing, Harbin
2024-12-01
Recruiting
Pre-Anesthesia Visit: Analysis of Coverage Rate of Visit Content and Surgical Patients' Understanding of Information
NCT06735183To Assess the Coverage of Anesthesiology Residents' Explanations of the Content of the Visit, Patients' Understanding of the Content of the Anesthesia Approach Through the Physician's Explanations
Anshi Wu
Observational
110
Beijing
2024-12-01
Recruiting
The Role of AAT After Abdominal Surgery Based on RWS
NCT06580197Acupuncture, Ear, Gastroparesis
Peking Union Medical College Hospital
Observational
159
Beijing
2024-12-01
Recruiting
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
NCT03547232Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple
Peking Union Medical College Hospital
Phase 4
1,504
Beijing, Guiyang, Baoding, Harbin, Dengzhou, Nanyang, Huaian, Nantong
2024-12-01
Not yet open
Impact of HI-NPPV Vs LI-NPPV on Tolerance Among AECOPD Patients
NCT06692023Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Beijing Chao Yang Hospital
Not applicable
20
Beijing
2024-12
Not yet open
A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
NCT06731829For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
78
Beijing
2024-12
Not yet open
Research on the Monitoring, Pathogen Screening, and Diagnostic System for Unexplained and Newly Emerging Acute Hepatitis
NCT06653140Hepatitis of Unknown Aetiology
Minghui Li
Observational
100
Beijing
2024-12
Not yet open
Combined Aerobic Exercise and Cognitive Training in Seniors With Genetic Susceptibility for Alzheimer's Disease
NCT05163067Alzheimer Disease
Xuanwu Hospital, Beijing
Not applicable
200
Beijing
2024-12
Not yet open
Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
NCT06671717Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Peking University People's Hospital
Not applicable
25
Beijing
2024-12
Not yet open
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
NCT06704828Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
20
Beijing
2024-12
Not yet open
Combined Aerobic Exercise and Cognitive Training in Seniors at Increased Risk for Alzheimer's Disease
NCT05163626Alzheimer Disease
Xuanwu Hospital, Beijing
Not applicable
200
Beijing
2024-12
Recruiting
Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7
NCT06020755Gestational Trophoblastic Neoplasia
DrugsActinomycin-D·Tislelizumab
Peking Union Medical College Hospital
Phase 2
17
Beijing
2024-12
Recruiting
CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NCT06646952Solid Tumor
Drug18F-FDG
Hua Zhu
Observational
30
Beijing
2024-12
Not yet open
Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery
NCT06663254Perioperative Volume Replacement, Hydroxyethyl Starch
Xiangya Hospital of Central South University
Phase 4
410
Zhengzhou, Changsha, Shenyang, Jinan, Xi'an, Beijing
2024-11-30
Recruiting
Effect of Preoperative Exercise Habits on Knee Function and Recurrence Rate After Anterior Cruciate Ligament Reconstruction
NCT06608394Anterior Cruciate Ligament Rupture
Peking University Third Hospital
Observational
361
Beijing
2024-11-30
Recruiting
Temporal Interference for Drug Resistant Epilepsy
NCT06708143Drug Resistant Epilepsy
Xuanwu Hospital, Beijing
Not applicable
30
Beijing
2024-11-30
Recruiting
A Study of BGM0504 in Participants with Type 2 Diabetes
NCT06716216Type 2 Diabetes Mellitus (T2DM)
BrightGene Bio-Medical Technology Co., Ltd.
Phase 3
537
Beijing
2024-11-29
Recruiting
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
NCT06459687Cervical Cancer
DrugsCisplatin/carboplatin·Paclitaxel·Bevacizumab
Lee's Pharmaceutical Limited
Phase 3
440
Hefei, Beijing, Wuhan, Changsha, Hangzhou
2024-11-28
Active, closed
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855Open Angle Glaucoma, Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
Phase 3
345
Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang
2024-11-28
Active, closed
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis๏ผšBDLL Chinese Cohort
NCT06649721Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
DrugsClofazimine·Delamanid·Bedaquiline·Levofloxacin
Huashan Hospital
Phase 3
120
Hefei, Beijing, Xiamen, Nanning, Liupanshui, Shijiazhuang, Harbin, Jiamusi
2024-11-27
Recruiting
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
NCT07260305Advanced or Metastatic Solid Tumors
Kangabio AUSTRALIA LTD PTY
Phase 1
57
Beijing, Shanghai
2024-11-27
Active, closed
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients
NCT06712771Homozygous Familial Hypercholesterolemia (HoFH)
Visirna Therapeutics HK Limited
Phase 3
46
Beijing
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324Non Small Cell Lung Cancer
DrugsTaletrectinib·Crizotinib
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
By invitation
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
NCT06763965Recurrent High-grade Glioma
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2
30
Beijing
2024-11-26
Recruiting
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
NCT06657703Systemic Lupus Erythematosus
DrugHC022
HC Biopharma Inc.
Phase 1
38
Beijing
2024-11-25
Recruiting
Atrial Shunt for the Treatment of Heart Failure With Reduced Ejection Fraction
NCT07820410Heart Failure With Reduced Ejection Fraction (HFrEF)
Beijing Anzhen Hospital
Phase 2/3
208
Beijing
2024-11-25
Recruiting
A Study of ES014 in Subjects With Advanced Solid Tumors
NCT06543056Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
15
Beijing
2024-11-25
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
NCT06688799Autoimmune Diseases
Beijing GoBroad Hospital
Phase 1/2
18
Beijing
2024-11-23
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
A Phase โ…ข Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
DrugsHLX22·Trastuzumab·Oxaliplatin·Capecitabine
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Active, closed
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT06639295Sinusitis, Nasal Polyps
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
243
Beijing
2024-11-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Recruiting
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
NCT06767800Gastroesophageal Adenocarcinoma
DrugsTQB2102·Penpulimab·Etoposide
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
204
Fuyang, Lu'an, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei
2024-11-21
Recruiting
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
NCT06648317Lung Cancer, Non-Small Cell, Lung Infection
Peking University Cancer Hospital & Institute
Observational
20
Beijing
2024-11-21
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula
NCT06686355Sepsis Induced Myocardial Dysfunction
Dongzhimen Hospital, Beijing
Phase 2
80
Beijing
2024-11-20
Recruiting
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
NCT06682169Graft-versus-host Disease
DrugsRovadicitinib·Mycophenolate Mofetil·Imatinib·Methotrexate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Recruiting
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
NCT07115238Alzheimer Disease, Neurofibrillary Tangle
Sinotau Pharmaceutical Group
Phase 3
354
Beijing
2024-11-20
Recruiting
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NCT06956001EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsFirmonertinib Mesilate·Pemetrexed Disodium·Cisplatin·Carboplatin
Allist Pharmaceuticals, Inc.
Phase 3
300
Beijing, Shandong
2024-11-19
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
NCT06641635Cervical Cancer, Adaptive Radiotherapy
Peking Union Medical College Hospital
Phase 3
440
Beijing
2024-11-19
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Carboplatin·Pembrolizumab
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Recruiting
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
NCT07514936Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
DrugsAclacinomycin·Azacytidine·Cytarabine·Chidamide
Chinese PLA General Hospital
Phase 3
120
Beijing
2024-11-18
Recruiting
Mts105 for Advanced Hepatocellular Carcinoma
NCT06689540Liver Cancer, Adult, Metastatic Liver Cancers, HCC - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Shen Lin
Phase 1
14
Beijing
2024-11-18
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
DrugLerodalcibep
Hasten Biopharmaceutical Co., Ltd.
Phase 3
210
Beijing, Guangzhou, Shijiazhuang, Daqing, Changsha, Nanchang, Binzhou, Heze
2024-11-16
Recruiting
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
NCT06134960Gastric Cancer, Pancreatic Cancer, Solid Tumor
Peking University
Phase 1
12
Beijing
2024-11-16
Not yet open
Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients
NCT06665880Drug Resistant Epilepsy, Traumatic Brain Injury Without Open Intracranial Wound
Xuanwu Hospital, Beijing
Observational
16
Beijing
2024-11-15
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Not yet open
A Study of CAR-T Cells Targeting Autoimmune Diseases
NCT06661811Autoimmune Diseases
Beijing Boren Hospital
Not applicable
12
Beijing
2024-11-15
Recruiting
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
NCT06873100Relapsing Polychondritis
DrugUpadacitinib
Peking University People's Hospital
Phase 1/2
30
Beijing
2024-11-15
Active, closed
Ultrasound-based Artificial Intelligence for Classification of Carpal Tunnel Syndrome
NCT06697392Carpal Tunnel Syndrome (CTS), Ultrasound, Artificial Intelligence (AI)
Peking University People's Hospital
Observational
500
Beijing
2024-11-15
Not yet open
EGFR Mutation Targeting Molecular Probe for PET Imaging
NCT06641674Cancer
Peking University Cancer Hospital & Institute
Observational
20
Beijing
2024-11-15
Not yet open
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
NCT06641453Hepatocellular Carcinoma (HCC)
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2024-11-15
Active, closed
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921Locally Advanced or Metastatic Breast Cancer
DrugsSIM0270·Exemestane·Everolimus·Fulvestrant
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Not yet open
A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection
NCT06679998Acute Ischemic Stroke (AIS)
Jiangsu Kanion Pharmaceutical Co., Ltd
Phase 1
56
Beijing
2024-11-14
Recruiting
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06775860Atopic Dermatitis
DrugICP-332
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
552
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan
2024-11-14
Active, closed
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
NCT06605885Asthma
AstraZeneca
Observational
202
Hohhot, Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou
2024-11-14
Recruiting
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors
NCT06728189Advanced Malignant Solid Tumors
Peking University Cancer Hospital & Institute
Phase 1
13
Beijing
2024-11-14
Recruiting
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
NCT06711471Gastric Cancer Adenocarcinoma Metastatic
LIN YANG
Phase 2
31
Beijing
2024-11-14
Recruiting
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
NCT06880913Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital
Phase 1/2
50
Beijing
2024-11-14
Active, closed
Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle
NCT06646419COPD
AstraZeneca
Observational
1,368
Anyang, Baise City, Beijing, Bijie, Changsha, Chenzhou, Chifeng, Chuzhou
2024-11-13
Active, closed
A Real-world Study to Assess Safety of OZURDEXยฎ (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
NCT06548568Diabetic Macular Edema
AbbVie
Observational
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao
2024-11-13
Recruiting
Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study
NCT06831435Depression, Bipolar Affective Disorder, Schizophenia Disorder, Psychiatric &Amp;or Mood Disorder
Peking University
Not applicable
325
Beijing
2024-11-13
Recruiting
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
NCT06714383Osteosarcoma
DrugsPirarubicin·Lobaplatin·Trilaciclib
Peking University People's Hospital
Phase 2
50
Beijing
2024-11-13
By invitation
Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis
NCT06976099Acute Pancreatitis (AP), Hypertriglyceridemia Acute Pancreatitis
Peking Union Medical College Hospital
Observational
1,000
Beijing, Guangzhou, Zunyi, Harbin, Changsha, Nanjing, Yangzhou, Dalian
2024-11-13
Recruiting
LIVERAGEโ„ข - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-11-12
Recruiting
Family-Based Moyamoya Susceptibility and Early Detection
NCT07517354Moyamoya Disease
Beijing Tiantan Hospital
Observational
700
Beijing
2024-11-12
Recruiting
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
NCT07029958EBV-T/NK LPD
Beijing Children's Hospital
Phase 4
48
Beijing
2024-11-12
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Recruiting
Development and Application of Precision Treatment Strategies for Common Mental Disorders
NCT06729541Depression - Major Depressive Disorder, Schizophrenia Disorders, Bipolar Disorder (BD)
Peking University
Not applicable
600
Beijing
2024-11-11
Active, closed
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
283
Beijing, Chengdu, Guangzhou, Shanghai
2024-11-11
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugLP352
Longboard Pharmaceuticals
Phase 3
367
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-11-11
Recruiting
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
NCT06647862Chronic Myelomonocytic Leukemia
DrugAzacitidine
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
170
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang
2024-11-11
Recruiting
Evaluating the Short-term Efficacy of Two Oscillation Techniques in Hypersecretive Mechanically Ventilated Patients
NCT06675942Hypersecretive Mechanically Ventilated Patients
Capital Medical University
Not applicable
24
Beijing
2024-11-10
Recruiting
Baricitinib in the Treatment of Intestinal Behรงet's Syndrome
NCT06849908Behcet Syndrome, Intestinal Type
Peking Union Medical College Hospital
Phase 2
56
Beijing
2024-11-08
Recruiting
Safety and Effectiveness of the Peripheral Balloon-Expandable Covered Stent System for Iliac Artery Stenosis/Occlusion. (SELECT)
NCT06605209Peripheral Artery Disease (PAD)
Zhejiang Zylox Medical Device Co., Ltd.
Not applicable
130
Beijing
2024-11-08
Active, closed
A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors
NCT06610227Advanced Solid Tumors
NING LI
Phase EARLY_PHASE1
18
Beijing
2024-11-08
Not yet open
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
NCT06606509Type1 Diabetes Mellitus
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Anqing, Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Quanzhou
2024-11-07
Recruiting
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)
NCT06548971Acute Ischemic Stroke, Cerebral Infarction
Capital Medical University
Phase 3
1,184
Bengbu, Suzhou, Beijing, Haidian, Pinggu, Tongzhou, Fuzhou, Xiamen
2024-11-07
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
DrugsBudesonide/Formoterol·Lunsekimig
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
Recruiting
Evaluation of Long-term Isokinetic Training of Knee Joint
NCT06674473Knee Injuries and Disorders
Peking University Third Hospital
Not applicable
12
Beijing
2024-11-06
Recruiting
Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)
NCT06880575Coronary Arterial Disease (CAD), ELDERLY PEOPLE
Beijing Hospital
Observational
10,139
Beijing
2024-11-06
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
NCT06566586B-cell Lymphoma
DrugTQB3702
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
By invitation
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
NCT06664970MDS
Peking Union Medical College Hospital
Phase 2
39
Beijing
2024-11-06
Recruiting
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
NCT06598735Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
290
Beijing
2024-11-05
Recruiting
Clinical Performance of Urine HPV Testing in Males
NCT06671210HPV, Self-sampling, Male
Peking University People's Hospital
Observational
150
Beijing
2024-11-04
Recruiting
Evaluating Modulation Effects of Temporal Interference Using SEEG
NCT06663969Deep Brain Stimulation, Drug Resistant Epilepsy
Xuanwu Hospital, Beijing
Not applicable
20
Beijing
2024-11-04
Recruiting
Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage
NCT06673602Cognitive Impairment, Intracerebral Hemorrhage
Qinhuangdao Hospital of Traditional Chinese Medicine
Phase 4
200
Beijing, Qinhuangdao, Kaifeng, Jinan, Weifang, Kunming
2024-11-04
Not yet open
Minimally Invasive Atlantoaxial Lateral Mass Joint Fusion (MIS-PALF) As a Surgical Treatment of Atlantoaxial Dislocation
NCT06678711Atlantoaxial Dislocation
Peking University Third Hospital
Not applicable
60
Beijing
2024-11-04
By invitation
The Effectiveness of Interventions Targeting Self-Perception of Aging in Older Adults with Subjective Cognitive Decline
NCT06622889Subjective Cognitive Decline (SCD)
Zheng Li
Not applicable
64
Beijing
2024-11-01
Recruiting
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
NCT06684600Esophageal Squamous Cell Carcinoma
DrugsDalpiciclib·Pyrotinib
Peking University
Phase 2
35
Beijing
2024-11-01
Recruiting
Effect of WBT for CI With Depression
NCT06968013Chronic Insomnia, Depression Disorders
Xuanwu Hospital, Beijing
Not applicable
84
Beijing
2024-11-01
Not yet open
Intelligent Analysis and Clinical Validation of Cerebral Small Vessel Disease on Magnetic Resonance Imaging๏ผšA Multi-center Study
NCT06667635Cerebral Small Vessel Disease
Chinese PLA General Hospital
Observational
1,000
Beijing
2024-11-01
Recruiting
Effects of Tai Chi on Chronic Insomnia Disorder Combined With Hyperarousal/Anxiety
NCT06967974Chronic Insomnia
Xuanwu Hospital, Beijing
Not applicable
80
Beijing
2024-11-01
Rows per page Showing 2901–3000 of 5484
Previous 28 29 30 31 32 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=30

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.